First Business Financial Services Inc. Cuts Position in Eli Lilly and Company $LLY

First Business Financial Services Inc. reduced its stake in Eli Lilly and Company (NYSE:LLY) by 9.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,601 shares of the company’s stock after selling 579 shares during the quarter. Eli Lilly and Company comprises approximately 0.4% of First Business Financial Services Inc.’s holdings, making the stock its 26th largest position. First Business Financial Services Inc.’s holdings in Eli Lilly and Company were worth $4,274,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Sumitomo Mitsui Financial Group Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $27,000. Evolution Wealth Management Inc. bought a new stake in Eli Lilly and Company during the 2nd quarter valued at about $29,000. Steph & Co. raised its holdings in Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares during the last quarter. Financial Gravity Companies Inc. bought a new position in shares of Eli Lilly and Company in the second quarter worth approximately $31,000. Finally, Bare Financial Services Inc grew its holdings in shares of Eli Lilly and Company by 263.6% during the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA grants Breakthrough Therapy designation to Lilly’s ovarian cancer candidate sofetabart (mipitecan), boosting the company’s oncology outlook and potential near-term regulatory value. Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation
• Positive Sentiment: SURMOUNT-REAL UK phase 4 update supports real‑world evidence for tirzepatide’s obesity benefit, which helps validate long-term market adoption and pricing power for Lilly’s GLP-1/dual-agonist franchise. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: Retatrutide trial shows potential knee osteoarthritis relief tied to obesity treatment, suggesting additional indications and expanded patient populations for Lilly’s obesity pipeline. Eli Lilly’s Retatrutide Trial Links Obesity Treatment With Knee Osteoarthritis Relief Potential
• Positive Sentiment: Lilly launches a Phase 2 trial for a new oral drug targeting diabetic nerve pain, expanding non-GLP-1 growth avenues and diversifying future revenue streams. Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain
• Neutral Sentiment: Lilly confirmed its Q4 2025 results and investor call for Feb. 4, giving the market a near-term event to reset guidance and expectations. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Analysts at Guggenheim trimmed LLY’s price target marginally (from $1,163 to $1,161) but kept a buy rating—little change to consensus upside but worth noting as analyst attention remains high. LLY: price target lowered by Guggenheim
• Neutral Sentiment: Market pieces and retrospectives highlight strong historical returns and positive analyst narratives (e.g., MarketBeat, Benzinga), supporting investor confidence but not constituting new catalysts. Here’s How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 5 Years
• Negative Sentiment: Commentary on Novo Nordisk’s new CEO and competitive strategy raises the profile of intense GLP-1 rivalry; investors may be watching pricing, market share, and promotional dynamics between LLY and Novo. Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent analyst reports. National Bankshares set a $1,286.00 price objective on shares of Eli Lilly and Company in a report on Monday, December 1st. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft upped their price target on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Leerink Partners set a $1,234.00 target price on Eli Lilly and Company in a research report on Monday, January 5th. Finally, CICC Research upped their target price on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Four analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $1,174.61.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,078.98 on Thursday. The stock has a market cap of $1.02 trillion, a P/E ratio of 52.79, a P/E/G ratio of 0.78 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The stock’s fifty day moving average is $1,055.07 and its 200 day moving average is $876.57. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the business posted $1.18 earnings per share. The business’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.